AU2004283425B2 - Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor - Google Patents

Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor Download PDF

Info

Publication number
AU2004283425B2
AU2004283425B2 AU2004283425A AU2004283425A AU2004283425B2 AU 2004283425 B2 AU2004283425 B2 AU 2004283425B2 AU 2004283425 A AU2004283425 A AU 2004283425A AU 2004283425 A AU2004283425 A AU 2004283425A AU 2004283425 B2 AU2004283425 B2 AU 2004283425B2
Authority
AU
Australia
Prior art keywords
dementia
tropane
disease
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283425A
Other languages
English (en)
Other versions
AU2004283425A1 (en
Inventor
Thomas Friedl
Joachim Mierau
Andreas Raschig
Jurgen Reess
Jorgen Scheel-Kruger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2004283425A1 publication Critical patent/AU2004283425A1/en
Assigned to NEUROSEARCH A/S reassignment NEUROSEARCH A/S Request for Assignment Assignors: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, NEUROSEARCH A/S
Application granted granted Critical
Publication of AU2004283425B2 publication Critical patent/AU2004283425B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2004283425A 2003-10-16 2004-10-05 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor Ceased AU2004283425B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03023635.0 2003-10-16
EP03023635 2003-10-16
EP04005819.0 2004-03-11
EP04005819 2004-03-11
PCT/EP2004/011093 WO2005039580A1 (en) 2003-10-16 2004-10-05 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

Publications (2)

Publication Number Publication Date
AU2004283425A1 AU2004283425A1 (en) 2005-05-06
AU2004283425B2 true AU2004283425B2 (en) 2010-07-08

Family

ID=34524707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283425A Ceased AU2004283425B2 (en) 2003-10-16 2004-10-05 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

Country Status (10)

Country Link
US (2) US20050154009A1 (https=)
EP (2) EP1675591B1 (https=)
JP (1) JP2007508336A (https=)
AT (1) ATE519486T1 (https=)
AU (1) AU2004283425B2 (https=)
CA (1) CA2542442C (https=)
DK (1) DK1675591T3 (https=)
MX (1) MXPA06003762A (https=)
NZ (1) NZ547152A (https=)
WO (1) WO2005039580A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
EP1675591B1 (en) * 2003-10-16 2011-08-10 NeuroSearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
AU2004290520A1 (en) * 2003-11-18 2005-06-02 Boehringer Ingelheim International Gmbh Solid pharmaceutical preparation form
EP1708707A1 (en) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
CA2553649A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
EP1755602A1 (en) * 2004-06-04 2007-02-28 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
RU2452474C2 (ru) * 2006-12-01 2012-06-10 Нитто Денко Корпорейшн Стабилизированная адгезивная композиция, содержащая донепезил
US20100062045A1 (en) * 2006-12-01 2010-03-11 Nitto Denko Corporation Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
RU2481826C2 (ru) * 2008-05-30 2013-05-20 Нитто Денко Корпорейшн Содержащий донепезил адгезивный препарат и упаковка для него
CN102046171B (zh) * 2008-05-30 2013-06-19 日东电工株式会社 经皮吸收制剂
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014085367A1 (en) * 2012-11-30 2014-06-05 P2D Inc. Substituted benztropine analogs for treatment of dementia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2020084065A1 (en) * 2018-10-24 2020-04-30 Saniona A/S Transdermal tropane compositions and methods for using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604354A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Antidepressant and antiparkinsonian compounds
EP0604352A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Aryl substituted heterocyclic compounds
EP0604355A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Akyl Substituted heterocyclic compounds
US5444070A (en) * 1992-12-23 1995-08-22 Neurosearch A/S Phenyl substituted heterocyclic compounds
WO1995028401A1 (en) * 1994-04-19 1995-10-26 Neurosearch A/S Tropane-2-aldoxine derivatives as neurotransmitter reuptake inhibitors
WO1997030997A1 (en) * 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use
WO2002002549A1 (en) * 2000-07-05 2002-01-10 Taisho Pharmaceutical Co., Ltd. Tetrahydropyridino or piperidino heterocyclic derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554626A (en) * 1896-02-11 murphy
US5554626A (en) * 1992-12-23 1996-09-10 Neurosearch A/S Substituted heterocyclic compounds as dopamine-reuptake inhibitors
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
JP2005508872A (ja) * 2001-05-23 2005-04-07 ニューロサーチ、アクティーゼルスカブ トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法
US20030008791A1 (en) * 2001-06-06 2003-01-09 Lonza Inc. Non-alcoholic hand sanitizer
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CA2515732A1 (en) * 2003-02-12 2004-08-26 Neurosearch A/S Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1675591B1 (en) * 2003-10-16 2011-08-10 NeuroSearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
EP1708707A1 (en) * 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
CA2553649A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
EP1755602A1 (en) * 2004-06-04 2007-02-28 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604354A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Antidepressant and antiparkinsonian compounds
EP0604352A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Aryl substituted heterocyclic compounds
EP0604355A2 (en) * 1992-12-23 1994-06-29 Neurosearch A/S Akyl Substituted heterocyclic compounds
US5444070A (en) * 1992-12-23 1995-08-22 Neurosearch A/S Phenyl substituted heterocyclic compounds
WO1995028401A1 (en) * 1994-04-19 1995-10-26 Neurosearch A/S Tropane-2-aldoxine derivatives as neurotransmitter reuptake inhibitors
WO1997030997A1 (en) * 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use
WO2002002549A1 (en) * 2000-07-05 2002-01-10 Taisho Pharmaceutical Co., Ltd. Tetrahydropyridino or piperidino heterocyclic derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRINGENBERG H: "Effect of Tacrine on EEG Slowing in the Rat: Enhancement by Concurrent Monoamine Therapy" NEUROBIOLOGY OF AGING, vol. 21, 2000, pages 135-143 *
SIMONSON W: "Promising Agents for Treating Alzheimer's Disease" AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, vol. 55, Suppl. 2, 1 November 1998, pages S11-S16 *

Also Published As

Publication number Publication date
EP1675591A1 (en) 2006-07-05
EP2269608A3 (en) 2011-02-16
US20050154009A1 (en) 2005-07-14
DK1675591T3 (da) 2011-11-14
EP1675591B1 (en) 2011-08-10
JP2007508336A (ja) 2007-04-05
CA2542442C (en) 2012-08-21
EP2269608A2 (en) 2011-01-05
AU2004283425A1 (en) 2005-05-06
CA2542442A1 (en) 2005-05-06
NZ547152A (en) 2009-12-24
WO2005039580A1 (en) 2005-05-06
US20100210626A1 (en) 2010-08-19
MXPA06003762A (es) 2006-06-14
ATE519486T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
AU2004283425B2 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
AU2005205882A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
AU781827B2 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
AU753077B2 (en) Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
US20050182090A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
HUP0201279A2 (en) Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
EP1750808B1 (en) Myricitrin compounds for treating sleeping disorders
US20190314354A1 (en) Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
EP1145714A1 (en) Drugs
CA2357901A1 (en) Combination treatment for depression and anxiety
MXPA01010904A (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion del conjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos a
EP1727547A1 (en) Compounds for the sustained reduction of body weight
KR20030024877A (ko) 중독성 질환의 치료용 화합물
WO1998031356A1 (en) Idebenone containing combination agent for treating alzheimer's disease
JPH10259126A (ja) アルツハイマー病治療・予防剤
MXPA06008113A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
WO2005089746A1 (en) Dosage titration for treatment of cognitive disorders
WO2003105815A1 (en) Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
JP2002522476A (ja) 血管拡張性頭痛の処置
JP2000273042A (ja) 医 薬
HU190714B (en) Process for the preparation of pharmaceutical compositions containing dibenzocycloheptadiene antidepressant and ergot alkaloid

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEUROSEARCH A/S

Free format text: FORMER APPLICANT(S): BOEHRINGER INGELHEIM INTERNATIONAL GMBH; NEUROSEARCH A/S

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired